P1VITAL PRODUCTS LIMITED - Key Persons
Colin T Dourish PhD DSc is Chief Executive Officer and one of the two founders and owners of P1 vital an innovative Clinical Research and Healthcare Organisation specialising in experimental medicine and novel therapies for CNS disorders. P1 vital and its affiliate company P1 vital Products provide innovative products and services for pharmaceutical and biotechnology companies developing novel therapies for the treatment of depression, anxiety, schizophrenia, cognitive disorders, eating disorders and obesity. For example, the P1 vital® Oxford Emotional Test Battery (ETB) is used to assess the efficacy of novel antidepressants in clinical trials and digital technology from the ETB was used in the development of i‑Spero for healthcare. Dr Dourish has extensive expertise in the commercialisation of products and services for mental health disorders and has led the commercial and market access strategy for i‑Spero in Europe and the USA.
Dr Dourish has a successful track record in CNS drug discovery and drug development in both major pharmaceutical and biotechnology companies. Prior to co-founding P1 vital, he was Senior Vice President Research and CSO of Vernalis, Research Director and co-founder of Cerebrus, Director of Neuropharmacology at Wyeth and Section Head at Merck.
Dr Dourish has over 400 publications in scientific and medical journals and has edited four books in the areas of Psychopharmacology, Neuroscience, Neurology and Psychiatry. He is an Honorary Fellow of the Department of Psychiatry at the University of Oxford. Dr Dourish received his BSc in Psychology and his PhD and DSc in Psychopharmacology from the Queen's University of Belfast and carried out postdoctoral research at the University of Saskatchewan in Canada and at the Institute of Neurology in London.
Gerry has considerable experience in the discovery and development of novel drugs for CNS disorders. Prior to co-founding P1 vital, Gerry was Senior Director at Merck's Neuroscience Research Centre, UK. He coordinated both clinical and preclinical in developing new drugs for the treatment of cognition and anxiety disorders. In this role Gerry developed new Experimental Medicine methods, to make rapid and cost-effective Go/No Go decisions in early drug development. More recently Gerry has been instrumental in the providing scientific leadership in the development of i‑Spero. He has also lead efforts to redesign the treatment pathway for depression in primary care that is enabled by PPLs innovative digital technology including i‑Spero, an initiative that is supported by funding of £810 K from Innovate UK. Gerry has over 100 scientific publications and is a visiting research fellow at the University of Oxford, and an Honorary Professor at the Department of Neuroscience at University of Nottingham. He is a member of executive committee of the European College of Neuropsychopharmacology (ECNP) also chair its Experimental Medicine Network. In 2016 the network successfully bid for a 16 M H2020 Innovative Medicines Initiative award to developed new approaches to the treatment of Schizophrenia, Alzheimer 's disease and Major Depressive Disorder. More recently he has championed efforts within ECNP to establish standards in mental health digital technologies and APPs. Gerry obtained his BSc and D.Phil. in Experimental Psychology at the University of Ulster. He has authored or co-authored over 100 scientific publications in the field of psychology, neuroscience and health technology.
- Member of the Clinical Advisory Board
- CHIEF OPERATIONS MANAGER
Jonathan Kingslake has a wealth of knowledge and expertise of business and IT management in both the healthcare and pharmaceutical sectors. As Chief Executive Officer of P1 vital Products Ltd he has provided strategic leadership and direction in developing a suite of digital solutions for the healthcare and pharmaceutical sectors. In particular, he has driven the research and development of i‑Spero in collaboration with Clinicians and GPs across the UK and Europe. Before this, he was the Chief Operating Officer of P1 vital Ltd for 8 years, a Clinical Research Organisation focused on mental health disorders; an independent consultant providing strategic and operational management expertise to pharmaceutical and biotechnology companies; 15 years at Merck & Co in various senior business operations and IT roles in R&D and Manufacturing.
Jonathan Kingslake received his BSc in Computer Studies from Southampton University.